Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Debt / NOTE 2.000% 8/1
-
Market price (% of par)
-
75.82%
-
Total 13F principal
-
$301,922,000
-
Principal change
-
-$22,500,000
-
Total reported market value
-
$235,262,000
-
Number of holders
-
12
-
Value change
-
-$17,055,998
-
Number of sells
-
2
Institutional Holders of AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 as of Q4 2018
As of 31 Dec 2018,
AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 was held by
12 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$301,922,000
in principal (par value) of the bond.
The largest 10 bondholders included
Athyrium Capital Management, LP, EdgePoint Investment Group Inc., HIGHBRIDGE CAPITAL MANAGEMENT LLC, UBS OCONNOR LLC, Allianz Asset Management GmbH, Tekla Capital Management LLC, AMERIPRISE FINANCIAL INC, Whitebox Advisors LLC, ORBIMED ADVISORS LLC, and Context Capital Management, LLC.
This page lists
12
institutional bondholders reporting positions
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.